The Government intends to set uniform prices for medicines for state order

The government intends to introduce unified marginal prices for medicines for all state order. This was reported by "Kommersant" with reference to the passport of the corresponding national project.

The marginal prices will be formed based on the results of the analysis of public procurement using the information and analytical system of monitoring and monitoring the procurement of drugs, the order for the creation of which President Vladimir Putin gave in August. The cost of developing the system is estimated at 70 billion rubles.

Using the system of the Ministry of Health and customers will be able to receive information about the proposals of suppliers, prices for medicines, the results of auctions and the execution of contracts. The information system will have to simplify the identification of the fact of conspiracy. The final version of the system is planned to be created by January 1, 2018.

On July 14, Putin instructed the heads of regions to take control of the pricing policy when purchasing medicines due to theiralmost two-fold rise in price .

At the end of August, the head of the Federal Antimonopoly Service Igor Artemyev said that the pharmaceutical market in Russia is one of the most criminalized . Prices for the same medicines sold under different names can vary 160 times. According to Artemyev, organized crime operates in Russia in the field of drug sale. "We are talking about the existence of thousands of cartels in medicines, we are talking about almost all tenders undergoing violations, we are talking about organized crime in this area - by the way, we are the first to talk about it - and we are confident that we have high prices for this reason - this is a conspiracy," he said.

On October 5, RBC said that the government intends to significantly reduce prices for expensive drugs. Officials of the Ministry of Health, the Ministry of Industry and Trade and the Federal Antimonopoly Service have already begun negotiations with the largest pharmaceutical companies. In the negotiations, it is planned to attract representatives of 22 companies to cooperation: Roche, Johnson & Johnson, Teva, Abbvie, Celgene, Biocad, R-Farm, F-Synthesis and others. The main goal of negotiations with pharmaceutical companies is to save budget funds allocated for the purchase of vital and most important drugs.